FDA approves Cobenfy for adults with schizophrenia
The U.S. Food and Drug Administration has approved Bristol Myers Squibb's Cobenfy (xanomeline and trospium chloride), a first ...
BMJ14h
Nomogram model for predicting medication adherence in patients with various mental disorders based on the Dryad database
Objective Treatment compliance among psychiatric patients is related to disease outcomes. How to assess patient compliance remains a concern. Here, we established a predictive model for medication ...
Graphic20h
Untreated bipolar disorder may lead to suicide - Psychiatrist
A psychiatrist, Dr Yennusom Maalug, has cautioned that, untreated bipolar or mood disorders could lead to serious mental and ...
TMCnet21h
Health Union Expands Industry-Leading Portfolio of Online Health Communities With New Focus in Mental Health and Cardiometabolic Conditions
New health communities include four focused on mental health — Bipolar.Mental-Health-Community.com, Depression.Mental-Health-Community.com, Postpartum.Mental-Health-Community.com, and ...
This biotech's stock could double if its treatment for major depressive disorder succeeds, says Mizuho
Mizuho reiterated its bullish stance on biotech Neumora Therapeutics Inc. on Wednesday, and predicted a positive outcome when the company reports data from a late-stage trial of its treatment for ...